All You Need to Know About Allogene Therapeutics (ALLO) Rating Upgrade to BuyZacks Investment Research • 06/04/25
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCOGlobeNewsWire • 06/01/25
Allogene Therapeutics: Still Looking Shaky, But Looking To Turn The Corner (Rating Upgrade)Seeking Alpha • 05/28/25
Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-CelGlobeNewsWire • 05/22/25
Allogene Therapeutics (ALLO) Loses -31.94% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 05/15/25
Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business UpdateGlobeNewsWire • 05/13/25
Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business UpdateGlobeNewsWire • 05/06/25
Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewsWire • 04/23/25
FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease DrugZacks Investment Research • 04/08/25
Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and SclerodermaGlobeNewsWire • 04/07/25
Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business UpdateGlobeNewsWire • 03/13/25
Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business UpdateGlobeNewsWire • 03/03/25
Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and AustraliaGlobeNewsWire • 02/25/25
Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical OncologyGlobeNewsWire • 02/13/25
Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune DiseasesGlobeNewsWire • 01/28/25
Allogene Therapeutics (ALLO) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 12/26/24